about
Ebola virus vaccines: an overview of current approachesTherapy of human papillomavirus-related diseaseHPV vaccine: Current status and future directionsComprehensive control of human papillomavirus infections and related diseasesAlternative dosage schedules with HPV virus-like particle vaccines.Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunityDeterminants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study.Papillomaviruses: Viral evolution, cancer and evolutionary medicineCirculating CXCR5⁺CD4⁺ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus VaccinesNaturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.The use of urine in the follow-up of HPV vaccine trials.Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine.Immunology and Immunotherapy of Head and Neck CancerHuman Papillomavirus (HPV) Infection: Molecular Epidemiology, Genotyping, Seroprevalence and Associated Risk Factors among Arab Women in Qatar.HPV prophylactic vaccination in males improves the clearance of semen infection.A review of clinical trials of human papillomavirus prophylactic vaccines.GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with Chlamydia trachomatis.Soil-Transmitted Helminth Infections Are Associated With an Increase in Human Papillomavirus Prevalence and a T-Helper Type 2 Cytokine Signature in Cervical Fluids.Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected SubjectsHuman papillomavirus molecular biology and disease association.Impact of HPV vaccination on anogenital warts and respiratory papillomatosisImmunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 proteinThe role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infectionSmoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort.Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: evidence from the EPIC cohort.The interplay between HPV and host immunity in head and neck squamous cell carcinoma.Human papillomavirus vaccination: where are we now?Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.Recent progress in vaccination against human papillomavirus-mediated cervical cancer.Ebola virus vaccines - reality or fiction?Novel Approaches for Vaccination Against HPV-Induced Cancers.Tumour virus vaccines: hepatitis B virus and human papillomavirus.Health care utilization in general practice after HPV vaccination-A Danish nationwide register-based cohort study.HPV SEROSTATUS PRE- AND POST-VACCINATION IN A RANDOMIZED PHASE II PREPAREDNESS TRIAL AMONG YOUNG WESTERN CAPE, SOUTH AFRICAN WOMEN: THE EVRI TRIAL.
P2860
Q26999232-0CEB094F-4464-462A-BCDD-B8C1CECED195Q27007473-E1135AC2-02C9-4F29-B082-9DEB784A6C84Q27026524-AFE59CA7-87F8-412D-B079-BD164D4127B3Q33772648-1A81BC26-475E-42D5-98BA-8EF995D2A41BQ34102466-3BEE3CF1-428E-46B6-A09A-5BAEA45DDCF2Q34352416-5456A685-444A-4690-ACC6-D7EFD0E6A064Q34587057-9B007156-D2B6-4992-BADB-AD755E7BECDDQ35166924-70204194-7994-415D-B7CF-6C79702E557AQ35762614-910BE6CF-34E6-4F15-A666-F3CEBFCE83C7Q35861286-E141FEB1-60BC-4C25-9304-DE1886E32E4EQ35886468-538F8D74-AF03-43F8-B0BB-7EA515B93DFFQ35886730-D1B03082-A37F-4AB8-8DA7-BEC35626C2EAQ35887407-2488CF11-B8C0-43FC-A70F-C6AAAD28E0D9Q35887553-F1A027CC-F5DC-48F1-B663-CFFDA9286463Q35887777-C80F81CC-2E0E-43FD-B4F1-B6A3F812B470Q36100837-1BB66ED2-5EF0-4B9E-9813-F2A44F3E721EQ36238267-3B58D121-E2D4-4CA4-BB7D-E68BE256AADFQ36252874-5B68FC49-81B5-4CE8-AF05-F1ADFD6A5DCBQ36259403-E5430A0E-1390-41BA-9097-3CC6CD662170Q36310924-461504C6-634D-41B0-8E3C-FB51AAFE515CQ36373913-B0A3C26C-4E3E-40D0-AAA3-95CC2C5E4D69Q36562854-32937D81-C8E6-48B4-8499-D4B5DBFA75F4Q36846030-D06758F8-983E-4C7E-8241-ED647694F8EEQ37130168-D1686F6B-0655-4CCF-A37A-7E20F92315D2Q37221868-E7B07585-CBEA-42B1-9575-AAA932A60E4BQ37257349-0068EE3B-55FC-45B0-B975-4FD6FA39E086Q37284313-757C3B38-226C-4297-B484-0561C95EB264Q37545001-44E1C96B-579A-4561-965A-88BFD91AB2EFQ37668390-E2E2B223-E4DC-4C18-8A8D-3BD6A858A0CAQ37845334-379A3E42-FAF8-48D6-8C92-4F72618B34ECQ37845338-B5A42FE1-A173-4964-A3BE-22E343963DDEQ38126455-0C0B2B22-9F87-4D07-82E8-EC5750E726FDQ38218612-C5FD1FAF-6497-4B50-9AD7-046E2F5CFD73Q38255277-692FD4E6-4396-491C-B729-EEB8AE7661B3Q38370782-3C284331-B03F-4574-B4D7-D8ABC4833DF0Q38881265-85596935-8AB0-4B89-9E1B-35559518AD8EQ39033362-338B2080-E394-43B7-9D5E-92D2F11752BFQ40046649-DE14E767-E811-4AE5-A96A-DB5387D83040Q40050809-2D07E692-83B7-47EB-B97E-832CA093DA92Q40211544-C71F4CBC-2ECC-4BCA-AEAA-6023A7866558
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Human papillomavirus vaccines--immune responses.
@en
type
label
Human papillomavirus vaccines--immune responses.
@en
prefLabel
Human papillomavirus vaccines--immune responses.
@en
P2093
P1433
P1476
Human papillomavirus vaccines--immune responses.
@en
P2093
Connie Trimble
Ligia A Pinto
Margaret Stanley
P356
10.1016/J.VACCINE.2012.04.106
P407
P478
30 Suppl 5
P577
2012-11-01T00:00:00Z